

DAY 2 RECAP

They're still going to know you didn't read the book





Cancer Progress New York, NY | May 7 - 8, 2019

www.therapeuticinsight.com www.cancerprogressbyDH.com

Panel #5: Payer/Access Panel

Ed Saltzman (moderator), Peter Bach, Roger Longman, Burt Zweigenhaft

- Special conditions required for a market to be competitive (e.g. lack of barriers to entry, perfect substitutes, etc.) rarely exist in cancer. Therefore, there's a significant divergence between drug price and clinical value.
 - Since market forces do not effectively regulate prices as they do in other consumer industries, value-based frameworks and postexclusivity price regulations are needed to close the gap between price and value.
- A lively debate ensued discussing the effectiveness of value-based contracts, such as outcomes-based contracts, to regulate prices.
 - Often outcomes-based contracts negotiate net discounts that are not sizeable relative to the uncertainty in performance, lower approval bars, etc. It could be more effective to reduce post-exclusivity drug prices to that of its' marginal cost-of-production via policy regulation.
- However, value-based contracts (VBC) are moving towards shifting risk onto manufacturers, rather than patients (e.g. Lentiglobin VBC - 20% upfront payment, 80% payment if treatment reduces # of transfusions) in an attempt to associate value with performance.
- In order to address accessibility to drugs, which is different from coverage, cost pressures must be understood from the patient perspective. Companies should understand the total cost of care delivery (supportive case, infusions, etc.) and plan for patient support services to increase access.

PERSPECTIVES

Frameworks for Assessing the Value Cancer Drugs: Purely an Academic Exercise?

🛨 f У 🛛

July/August 2016 PDF Joshua P Cohen, PhD Login or Register Affiliation: Tufts Center for the Study of Drug Development, Boston, MA to download PDF Disclosures: The author reports no financial relationships. Citation: Journal of Clinical Pathways. 2016;2(0):29-33. Received May 26, 2016; Accepted July 13, 2016.

Abstract: As the cost of prescription drugs increases, pavers and providers alike

have attempted to deta cancer. In this article, t have been recently dev Taking into considerati

By MATTHEW HERPER @matthewherper and ED SILVERMAN @Pharmalot / APRIL 16, 2019

determine the prices o whether these newly e likely to have an impac prices of cancer drugs treatments. Finally, the discussed as likely hav reimbursement. STAT

Ed or

analyst/AC


<image>



Panel #6: IO Session II: IO Targets and Platforms - Target Versus Modality - What Are the Keys to the Kingdom? Joel S. Sandler (moderator), Frank Borriello, Louis Matis, Eric Poma, Dan Shoemaker

- The diversity of modalities (cell-based, biologics) has dramatically increased in the past few decades, with emergence of technologies along a risk-benefit spectrum.
- Target selection must be considered within the context of modality properties to achieve optimal alignment (e.g. anti-CD19 and -BCMA CARTs vs. anti-CD20 mAbs).
- Lead programs comprised of novel modalities should be de-risked with incorporation of validated targets.
- Panelists agreed that initial positioning must be focused on addressing white space, though next-wave modalities could ultimately supplant the entrenched SoC.
- TAA-based targeting or effector-cell redirecting regarded as an effective means to de-risk and facilitate biomarkerguided patient selection, though at the possible expense of antigen escape and associated resistance over time.

Modalities Positioned Along a Spectrum of Risk and Benefit



Finding the Optimal Target-Modality Pairing

• E.g. α -CD20 mAbs vs. α -CD19 CARTs in NHL

PAIRING SUMMER PRODUCE WITH CABERNET SAUVIGNON

- Key considerations include:
 - Expression pattern (on- vs. off-tumor targeting)
 - Target biology (immunogenicity, oncogenicity)
 - Turnover rate and mechanism
 - Presence, types of proximal effector cells (warm vs. cold tumors)
 - IP, CMC, and other logistical considerations





Cancer Progress New York, NY | May 7 - 8, 2019

www.cellohealthbioconsulting.com

www.therapeuticinsight.com www.cancerprogressbyDH.com

Panel #7: Gynecological & Breast Cancers, Much Progress, Much to Do: How Novel Therapies from PARPs to Immunotherapies Are Transforming Care


James T. Lee (moderator), Brian Leyland Jones, Martin Lehr, Patrick Mahaffy, Dmitriy Zamarin

- In light of the approvals of PARP inhibitors and immunotherapies, there is still a significant unmet need in gynecological and breast cancers.
- Largest hurdle that is yet to overcome is finding a way to treat those that do not respond to the current therapeutics, which is still a large percentage of TNBC and HR+BC refractory to CDK4/6 inhibitors.
- Significant issues exist in identifying novel targets that will work in ovarian cancer, driven by the unique nature of the disease where driver mutations are less frequent and even when new targets are identified, it is difficult to validate in vivo.
- The future may be identifying the optimal combination partners with both PARP inhibitors and immunotherapy, but could end up being a very empirical exercise vs a more thoughtful one.

	6000				_										Ja	me	es	
	5000-																	
(nln)	4000-																	
WW Sales US \$ (min)	3000-																	
WW S	2000-																	
	1000-																	
	0	2011-	2012-	2013-	2014 -	2015-	2016-	2017-	2018-	2019 -	2020-	2021-	2022-	2023-	2024-			
		Other Veliparit		^			izenna		Oncolog	w)		ula (GSK parza (A						

Breast Cancer Clinical Trials Targets

Discover the different proteins, pathways, and platforms that scientists and physicians are pursuing to develop new cancer treatments. Use this information to consider your clinical trial options.





Panel #8: Biotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Different New?

Jeffrey M. Bockman (moderator), Jean Chang, Jane Dancer, Kapil Dhingra, Helen Tayton-Martin, Jill O'Donnell-Tormey

- Over the past 4 years Immuno-Oncology (IO) deal-making has been at ٠ the forefront of Oncology partnerships, with most of the top 10 deals in cancer by upfronts being for IO licensing or M&A
- Despite the pace and size of deals slowing in light of high-profile ٠ stumbles (e.g. IDO inhibitors), there is a continued hunger for IO assets, novel MOAs and modalities; so, the question must be raised as to how deal-making is changing, or needs to change in the future.
- Biotechs face a challenge in weighing the investment in a deal versus ٠ further validating their programs to inflect value.
- Discussion of more innovative deals being done biotech-to-biotech ٠ rather than biotech-pharma ensued; not a new BD mantra but, perhaps newer to IO.
- Questions remain on how to control the proliferation of thinly ٠ differentiated CPI's and 'me-too' programs, while simultaneously maintaining competition to drive down cost.
- How do we make sure that great programs are not lost that may be ٠ transformative or only simply alternatives that can be important for giving patients more options?

			rted to Dominate	е Тор		,	Jeff
		Top 1	0 Deals by Upfront Value (\$M): 2015				
Rank	Company	Deal Partner/ Product Source	Product	Phase			
1	Celgene	Juno Therapeutics	JCAR017	Phase 1/2			
2	Sanofi	Regeneron Pharmaceuticals	REGN2810	Phase 1			
3	Celgene	AstraZeneca	Durvalumab	Research	450		120
4	Medivation	BioMarin Pharmaceutical	Talazoparib	Phase 3	410	160	570
5	Bristol-Myers Squibb	Five Prime Therapeutics	FPA008	Phase 2	350	1,390	1,740
6	Novartis	GlaxoSmithKline	Arzerra S.C.	Phase 3	300	734	1,034
7	AstraZeneca	Innate Pharma	Monalizumab	Phase 2	250	1,025	1,275
8	Novartis	Aduro Biotech	MIW815	Preclinical	250	500	750
9	Celgene	Nurix	Celgene-Nurix Immuno-oncology Program	Research	150	405	555
10	Bristol-Myers Squibb	Bavarian nordic	Prostvac	Phase 3	140	835	975
	-41-11	Тор	10 Deals by Total Value (\$M): 2015	1000	100	10	100
Rank	Company	Deal Partner/ Product Source	Product	Phase	Unfront*	Milestones	Total
1	Amgen	Xencor	Anti CD3 X CD38 MAb Program	Preclinical	45	1,700	1,745

2017: Upfronts in IO Drop, More Backloading – Maturing Vision?

Rank	Company	Deal Partner/ Product Source	Product(s)	Phase	Upfront*	Milestones	Total (Upfront + Milestone
Name	Company	Deal Partner/ Product source		Phase	opmont-	milestones	Total (Optront + Milestone
1	Merck	AstraZeneca	Lynparza, Selumetinib with PD-L1/PD-1 inhibitors	Marketed	1,600	6,150	7,750
2	Ipsen	Merrimack	Onlvyde	Marketed	575	450	1,025
3	Celgene	BelGene	BGB-A317	Phase 2	413	980	1,393
4	Bayer	Loxo	Larotrectinib	Phase 2	400	1,200	1,600
5	L&L	Genscript	LCAR-B38M	Phase 1/2	350	Undisclosed	350
6	TerSera	AstraZeneca	Zoladex	Marketed	250	70	320
7	Incyte	MacroGenics	MGA012	Phase 1	150	750	900
8	Bristol-Myers	Halozyme	Multiple	NA	105	1,760	1,865
9	Eli Lilly	CureVac	Multiple	Preclinical	103	1,700	1,803
10	Jazz Pharmaceuticals	ImmunoGen	IMGN632, IMGN779	Phase 1	75	Undisclosed	75



		т	op 10 Deals by Upfront Value (\$M):	2019			
Rank	Company	Deal Partner/Product Source	Product(s)	Phase	Upfront	Milestones	Total (Upfront + Milestones)
1	BMS	Celgene	Multiple	Multiple	35,000	N/A	74,000
2	Eli Lilly	Loxo Oncology	Multiple	Multiple	7,234	N/A	7,234
3	lpsen	Clementia Pharmaceuticals	Palovarotene	Phase 3	1,000	263	1,263
4	GSK	Merck KGaA	Bintrafusp alfa	Phase 2	343	3,870	4,214
5	Genentech	Adaptive Biotechnologies	Off-the-shelf TCR cell therapies	Preclinical	300	2,000	2,300
6	Merck	Immune Design	Multiple	Multiple	248	N/A	248
7	Aurobindo Pharma	Spectrum Pharma	Multiple	Multiple	160	140	300
8	Genentech	Xencor	IL-15 antibodies	Preclinical	120	340	460
9	AbbVie	Tizona Therapeutics	TTX-030 and CD39 programs	Preclinical	105	N/A	>105
10	AbbVie	TeneoBio	TNB-383B	Preclinical	90	N/A	90>
			Top 10 Deals by Total Value (\$M): 2	2019			
Rank	Company	Deal Partner/Product Source	Top 10 Deals by Total Value (\$M): 2 Product(s)	2019 Phase	Upfront	Milestones	Total (Upfront + Milestones)
Rank 1	Company BMS				Upfront 35,000	Milestones N/A	Total (Upfront + Milestones) 74,000
		Deal Partner/Product Source	Product(s)	Phase			
1	BMS	Deal Partner/Product Source Celgene	Product(s) Multiple	Phase Multiple	35,000	N/A	74,000
1 2	BMS Eli Lilly	Deal Partner/Product Source Celgene Loxo Oncology	Product(s) Multiple Multiple	Phase Multiple Multiple	35,000 7,234	N/A N/A	74,000 7,234
1 2 3	BMS Eli Lilly GSK	Deal Partner/Product Source Celgene Loxo Oncology Merck KGaA	Product(s) Multiple Multiple Bintrafusp alfa	Phase Multiple Multiple Phase 2	35,000 7,234 343	N/A N/A 3,870	74,000 7,234 4,214
1 2 3 4	BMS Eli Lilly GSK NJCTTQ	Deal Partner/Product Source Celgene Loxo Oncology Merck KGaA Abpro	Product(s) Multiple Multiple Bintrafusp alfa Multiple	Phase Multiple Multiple Phase 2 Preclinical	35,000 7,234 343 N/A	N/A N/A 3,870 4,000	74,000 7,234 4,214 4,000
1 2 3 4 5	BMS Eli Ully GSK NJCTTQ Genentech	Deal Partner/Product Source Celgene Loxo Oncology Merck KGaA Abpro Adaptive Biotechnologies	Product(s) Multiple Multiple Bintrafusp alfa Multiple Off-the-shelf TCR cell therapies	Phase Multiple Multiple Phase 2 Preclinical Preclinical	35,000 7,234 343 N/A 300	N/A N/A 3,870 4,000 2,000	74,000 7,234 4,214 4,000 2,300
1 2 3 4 5 6	BMS Eli Ully GSK NJCTTQ Genentech Ipsen	Deal Partner/Product Source Celgene Loxo Oncology Merck KGaA Abpro Adaptive Biotechnologies Clementia Pharmaceuticals	Product(s) Multiple Bintrafusp alfa Multiple Off-the-sheff TCR cell therapies Palovarotene	Phase Multiple Multiple Phase 2 Preclinical Preclinical Phase 3	35,000 7,234 343 N/A 300 1,000	N/A N/A 3,870 4,000 2,000 263	74,000 7,234 4,214 4,000 2,300 1,263
1 2 3 4 5 6 7	BMS Eli Lilly GSK NJCTTQ Genentech Ipsen Jazz Pharma	Deal Partner/Product Source Celegne Lozo Oncology Merck KGaA Abpro Adaptive Biotechnologies Clementia Pharmaceuticals Codiak Biosciences	Product(s) Multiple Birtrafusp alfa Multiple Off-the-shelf TCR cell therapies Palovarotene Multiple Exosome Programs	Phase Multiple Phase 2 Preclinical Preclinical Phase 3 Preclinical	35,000 7,234 343 N/A 300 1,000 56	N/A N/A 3,870 4,000 2,000 263 1,020	7,234 4,214 4,000 2,300 1,263 1,076





The Biden Cancer Initiative: Helping to build the cancer research and care system you think we already have

Speaker: Gregory C. Simon, President, Biden Cancer Initiative

- There is a distinct lack of organization in the healthcare system. Due to its impervious nature, the system has not accepted reforms and improvements in decades. For example, the transition from chronic medications to now curative treatments is raising huge debates since the system itself was not designed for cures.
- The scientific discovery process is highly isolated between labs, becoming more of a competition, rather than a group effort to advance cancer therapeutics.
 - The Biden Cancer Initiative is taking steps towards promoting research data sharing, along with clinical and medical record sharing. Investigators have extreme biases and knowledge solely on their research, but not what is happening outside their labs and in patients. Along with lack of crucial data sharing, a great portion of published data is yet to be successfully replicated.
- Drug pricing is based on pharma's fear of the future market, while insurance companies worry about the present events impacting their revenue.
 - Pharma has immense capital invested in their drugs, and the emergence of competitors in the market forces pharma to frontload their costs onto the price of the drug. Insurance companies cannot hedge their costs the way pharma does.
- Copays for cancer drugs are destroying the patients future. They force patients into choosing between bankruptcy or treatment. Questions arise now on how to help patients avoid these costs when they have zero economic power on the drug market.
- How do we organize the healthcare system such that patients are at the center of attention?

Cancer Progress New York, NY | May 7 - 8, 2019

Analyst/AC









Panel #9: Insights from Heme Malignancies: Making Breakthrough Conventional and Unconventional Therapies Accessible Beyond Niche Blood Cancer Patients Michael C. Rice (moderator), Chris Bowden, Lee Greenberger, Dan Shoemaker, Vatnak Vat-Ho

• XX







Panel #10: Oncology Innovation Powered by Investments and Competition from China

James T. Lee (moderator), Iris Luo, Ian Somaiya, Ian Woo, Jack Wu

- Significant investments in oncology are coming out of China, from the investors and biotechs, driving competition and valuation in many assets leading to bidding wars on hot innovative oncology assets in the West.
- The interest in China as both a source of dilutive and nondilutive funds has led many Western companies to form their China strategy on how to engage Chinese companies/firms.
- Conversely, Chinese biotechs are striving to expand their portfolio in China and also globally, and with the recent regulatory changes and financial incentives in building the portfolio with near-term de-risked assets, China is generating significant interest in Western companies that have a new set of partners to align with.
- The duality of the cross-border investments/dealmaking is making China front and center and not to be ignored by the global pharmaceutical and biotech industry.

China BioPharma is Seeing an Unprecedented Boom Driven Policy, Money, and Need

Regulatory:


- China joins ICH harmonizing global clinical development regulations/standards
- Chinese NMPA speeds up clinical development process and opening up for global development
- Accelerated approval set up for innovative therapeutics that are marketed overseas


Finance:

- China putting economic force behind the industry by building biotech parks, providing subsidies and incentives for biotechs to develop innovative products
- Chinese investors have raised significant capital to help the biotech boom both domestically and cross-borders, though new CFIUS process may become limiting
- HKEX open to pre-revenue biotechs, with recent success of Cstone, Innovent and others, but also cautionary tales of others (Ascletis, Beigene)

Need for Therapeutics:

 Growing patient population, especially related to cancer, where innovative therapeutics are needed.







Cancer Progress New York, NY | May 7 - 8, 2019

James

On track to nearly double again to \$21B in 2018